ILDONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,280 KRW | +1.39% |
|
+1.73% | -15.86% |
| 2023 | Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea | MT |
| 2023 | Il Dong Pharmaceutical Introduces New R&D Unit Yunovia | MT |
Strengths
- With a P/E ratio at 12.18 for the current year and 7.82 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.86% | 310M | - | - | |
| +25.83% | 661B | C+ | ||
| +27.00% | 566B | B | ||
| -6.76% | 352B | C+ | ||
| +20.34% | 332B | B- | ||
| +3.00% | 283B | C+ | ||
| +13.09% | 231B | B+ | ||
| +5.46% | 200B | B- | ||
| -9.61% | 195B | A+ | ||
| -6.26% | 145B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A249420 Stock
- Ratings Ildong Pharmaceutical Co., Ltd.
